How many drugs treat Hypoalphalipoproteinemia?

Drug Landscape tracks 5 marketed treatments for Hypoalphalipoproteinemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hypoalphalipoproteinemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hypoalphalipoproteinemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypoalphalipoproteinemia (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hypoalphalipoproteinemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Trilipix	CHOLINE FENOFIBRATE	AbbVie	Peroxisome Proliferator Receptor alpha Agonist	Fatty acid-binding protein, intestinal	2008-01-01
Tricor (Micronized)	FENOFIBRATE	Salix	Peroxisome Proliferator Receptor alpha Agonist [EPC]	PPARα	1993-01-01
Mevacor	LOVASTATIN	Merck & Co.	HMG-CoA Reductase Inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1987-01-01
Zocor	simvastatin	Merck & Co.	HMG-CoA Reductase Inhibitor [EPC]	Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Myoinositol	Myoinositol	University of Colorado, Denver

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck & Co. · 2 drugs in Hypoalphalipoproteinemia
· 1 drug in Hypoalphalipoproteinemia
AbbVie · 1 drug in Hypoalphalipoproteinemia
Salix · 1 drug in Hypoalphalipoproteinemia
University of Colorado, Denver · 1 drug in Hypoalphalipoproteinemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hypoalphalipoproteinemia:

Cite this brief

Drug Landscape (2026). Hypoalphalipoproteinemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypoalphalipoproteinemia. Accessed 2026-06-10.

Hypoalphalipoproteinemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing